TD Asset Management
AIMT

TD Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

TD Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100,776
Closed -$1.68M – 1424
2020
Q2 		$1.68M Buy
100,776
+2,800
+3% +$47.5K ﹤0.01% 920
2020
Q1 		$1.41M Sell
97,976
-12,100
-11% -$309K ﹤0.01% 908
2019
Q4 		$3.68M Buy
110,076
+7,700
+8% +$215K 0.01% 785
2019
Q3 		$2.14M Buy
102,376
+2,300
+2% +$47K ﹤0.01% 896
2019
Q2 		$2.08M Buy
100,076
+5,400
+6% +$111K ﹤0.01% 898
2019
Q1 		$2.12M Sell
94,676
-3,200
-3% -$75.3K ﹤0.01% 890
2018
Q4 		$2.34M Sell
97,876
-151
-0.2% -$3.91K ﹤0.01% 876
2018
Q3 		$2.67M Buy
98,027
+9,100
+10% +$257K ﹤0.01% 925
2018
Q2 		$2.39M Buy
88,927
+2,100
+2% +$64.3K ﹤0.01% 906
2018
Q1 		$2.76M Buy
86,827
+26,124
+43% +$919K ﹤0.01% 819
2017
Q4 		$2.3M Buy
60,703
+23,025
+61% +$743K ﹤0.01% 852
2017
Q3 		$934K Sell
37,678
-400
-1% -$8.62K ﹤0.01% 1050
2017
Q2 		$783K Buy
38,078
+6,400
+20% +$122K ﹤0.01% 1102
2017
Q1 		$688K Sell
31,678
-400
-1% -$8.21K ﹤0.01% 1133
2016
Q4 		$656K Buy
32,078
+600
+2% +$12.3K ﹤0.01% 1122
2016
Q3 		$472K Buy
31,478
+18,178
+137% +$245K ﹤0.01% 1198
2016
Q2 		$144K Hold
13,300
– – ﹤0.01% 1352
2016
Q1 		$180K Sell
13,300
-1,000
-7% -$15.6K ﹤0.01% 1317
2015
Q4 		$264K Buy
+14,300
New +$265K ﹤0.01% 1265

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TD Asset Management's AIMT Position: Q3 2020 in Review

TD Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 100,776 shares — an estimated $1.68M sold.

TD Asset Management first reported a position in AIMT in Q4 2015 and held it in 19 quarters. The position peaked at $3.68M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • TD Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • TD Asset Management sold 100,776 Aimmune Therapeutics shares in Q3 2020, an estimated $1.68M.
  • TD Asset Management first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 19 quarters.
  • TD Asset Management's Aimmune Therapeutics position peaked at $3.68M in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on TD Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.